NL-201

NL-201 is an immunotherapy drug candidate undergoing a Phase 1 human clinical trial in cancer patients as of May 2021.^[1] It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington.^[2]

History[]

The predecessor of NL-201, neoleukin-2/15, was first described and published on Nature magazine in January 2019.^[2] The citizen science distributed computing project Rosetta@home, based at the University of Washington, contributed with "forward folding" experiments that helped validate protein designs of neoleukin-2/15, from which NL-201 was further developed by Neoleukin Therapeutics, a biopharmaceutical company that originated at the IPD.^[3]^[4]

The Phase 1 human clinical trial began on May 5, 2021.^[5]

References[]

^ Neoleukin Therapeutics, Inc. (2021-05-25). "A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer". Cite journal requires |journal= (help)
^ Jump up to: ^a ^b Silva, Daniel-Adriano; Yu, Shawn; Ulge, Umut Y.; Spangler, Jamie B.; Jude, Kevin M.; Labão-Almeida, Carlos; Ali, Lestat R.; Quijano-Rubio, Alfredo; Ruterbusch, Mikel; Leung, Isabel; Biary, Tamara (2019-01-09). "De novo design of potent and selective mimics of IL-2 and IL-15". Nature. 565 (7738): 186–191. doi:10.1038/s41586-018-0830-7. ISSN 1476-4687. PMC 6521699.
^ "Another publication in Nature describing the first de novo designed proteins with anti-cancer activity". boinc.bakerlab.org. Retrieved 2021-06-22.
^ Therapeutics, Neoleukin (June 2020). "NL-201: A de novo CD25-independent combined IL-2 and IL-15 receptor agonistdesigned to selectively stimulate anti-tumor CD8+ effector T and NK cells" (PDF). Neoleukin Therapeutics. Retrieved 2021-06-22.
^ "Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial | Neoleukin Therapeutics, Inc". investor.neoleukin.com. Retrieved 2021-06-22.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] Neoleukin Therapeutics, Inc. (2021-05-25). "A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer". Cite journal requires |journal= (help)

[:0-2] Jump up to: ^a ^b Silva, Daniel-Adriano; Yu, Shawn; Ulge, Umut Y.; Spangler, Jamie B.; Jude, Kevin M.; Labão-Almeida, Carlos; Ali, Lestat R.; Quijano-Rubio, Alfredo; Ruterbusch, Mikel; Leung, Isabel; Biary, Tamara (2019-01-09). "De novo design of potent and selective mimics of IL-2 and IL-15". Nature. 565 (7738): 186–191. doi:10.1038/s41586-018-0830-7. ISSN 1476-4687. PMC 6521699.

[3] "Another publication in Nature describing the first de novo designed proteins with anti-cancer activity". boinc.bakerlab.org. Retrieved 2021-06-22.

[4] Therapeutics, Neoleukin (June 2020). "NL-201: A de novo CD25-independent combined IL-2 and IL-15 receptor agonistdesigned to selectively stimulate anti-tumor CD8+ effector T and NK cells" (PDF). Neoleukin Therapeutics. Retrieved 2021-06-22.

[:5-5] "Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial | Neoleukin Therapeutics, Inc". investor.neoleukin.com. Retrieved 2021-06-22.

[1]

[2]

[3]

[4]

[5]